Tolero Pharmaceuticals Announces Presentation At American Association for Cancer Research Describing A Relationship Between Biomarkers And Response To Alvocidib In Patients With Chronic Lymphocytic Leukemia

Published: Apr 07, 2014

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

Tolero Pharmaceuticals, Inc., a clinical-stage company developing treatments for serious hematological diseases, today announced that a poster related to its development program alvocidib, a potent cyclin-dependent kinase in development for a variety of hematologic disorders, was presented at the 105th Annual Meeting of the American Association for Cancer Research (AACR) in San Diego. The poster, “Bcl-xL Dependence Predicts Response to Alvocidib in Chronic Lymphocytic Leukemia Patients,” was presented on Sunday, April 6, 2014, at 1:00 p.m. in collaboration with Eutropics Pharmaceuticals, The Translational Genomics Research Institute, Ohio State University and the Duke Cancer Institute.

Help employers find you! Check out all the jobs and post your resume.

Back to news